title: Treatment of hepatitis C in 2011.
abstract: New knowledge on the treatment of Hepatitis C is accruing at an extraordinarily rapid rate and my aim in this editorial based on a talk I gave at the Pakistan Society of Gastroenterology Annual International Congress this year, is to outline how patients may be treated both currently and over the next two to three years.
authors.forename: Roger
authors.initials: R
authors.lastname: Williams
authors.forename: Aamir Ghafoor
authors.initials: AG
authors.lastname: Khan
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004282:Documentation; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D010154:Pakistan / Q000453:epidemiology; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D007372:Interferons; D011392:Proline